19:56:27 EDT Mon 17 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Diagnos Inc (3)
Symbol ADK
Shares Issued 76,648,586
Close 2024-04-16 C$ 0.30
Market Cap C$ 22,994,576
Recent Sedar Documents

Diagnos trying to get HC, FDA OK for four AI modules

2024-04-16 15:53 ET - News Release

Mr. Andre Larente reports

DIAGNOS TO EXPEDITE APPLICATION FOR MEDICAL DEVICE LICENSE TO HEALTH CANADA AND US FDA RELATED TO ITS 4 NEW ANALYSIS MODULES, AND IS PLANNING ISO 27001 CERTIFICATION

Diagnos Inc. is working on getting new Health Canada and Food and Drug Administration approval on four additional AI (artificial intelligence) analysis modules for commercialization during Q3 2024.

These additions to Diagnos's service will provide the company's customers with a flexible AI-assisted image processing and analysis solution for the detection of a wide range of retinopathies in a general population. Specifically, the new modules aim to assist health care professionals in identifying generally abnormal optical coherence tomography retinal images, and in the grading of Fundus images as it relates to signs of AMD (age-related macular degeneration), DR (diabetic retinopathy) or HR (hypertensive retinopathy).

"These soon to be licensed AI-empowered analytic modules have been developed in a manner that meet the current and upcoming guidelines related to AI-powered medical devices from regulators and legislators around the world. Artificial intelligence has already made its way into our lives and is poised to take a privileged role in patient care, patient management and in the clinical workflows of multiple medical specialties. There is no limit in application of artificial intelligence in medicine, it has immense potential to help and support health care professionals in improving clinical outcomes and the overall quality of life of their patients," said Andre Larente, president of Diagnos.

These new AI analytic modules will provide Diagnos with the opportunity to grow its revenue faster. The modernization of its Health Canada licence was required by both current clients, the Quebec government as well as being a prerequisite by Essilor Luxottica in order to distribute the company's services in Canada, as well as for a future United States market. Diagnos is also working toward its ISO 27001 cybersecurity application, a certification that is requested from the company's customers and prospects.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modification and development of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.